capecitabine + eribulin

Capecitabine + eribulin is a combination chemotherapy regimen consisting of two distinct small molecule agents, capecitabine and eribulin. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a pyrimidine analog that inhibits DNA synthesis by interfering with thymidylate synthase, leading to cytotoxicity in rapidly dividing cells. Eribulin mesylate is a synthetic analog of halichondrin B and acts as a non-taxane microtubule dynamics inhibitor; it binds to the growing ends of microtubules, preventing their elongation and causing irreversible mitotic blockade. This combination has been investigated primarily for the treatment of breast cancer—including metastatic breast cancer (MBC) and early-stage HER2-negative, ER-positive breast cancer—where it has demonstrated promising antitumor activity with manageable toxicity profiles due to non-overlapping side effects. The regimen aims to leverage potential synergistic effects while minimizing cumulative toxicity[1][2][3][4].

Other names

eribulin plus capecitabineeribulin and capecitabine